Sunday, 23 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· November 13, 2025

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

View original at globenewswire.com
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EQ504 has potential to be a first-in-class, oral and colon-targeted therapeutic for ulcerative colitis

    80% confidence

  • Initial tranche of financing is expected to fund Company operations through 2027

    80% confidence

  • AhR modulation is a differentiated and multi-modal approach to decreasing tissue inflammation while promoting tissue repair

    80% confidence

  • Cash and cash equivalents on the balance sheet as of September 30, 2025 are capable of funding currently planned operations through 2027

    80% confidence

  • Equillium expects to be ready to initiate Phase 1 clinical study in mid-2026 with potential to achieve proof-of-concept with addition of UC patient cohorts following SAD/MAD portion

    80% confidence

  • EQ504 is a potent and selective AhR modulator that may be administered orally and is formulated to target the colon, representing a next-generation therapeutic to treat UC locally

    80% confidence

  • EQ504 has broad therapeutic potential in UC as a potential standalone oral therapy, or in combination with other therapeutic approaches

    80% confidence

  • AhR modulation is clinically validated in skin and GI diseases through VTAMA and botanical indigo naturalis

    80% confidence

Cited in these Via News reports